On Friday, ARRIS Group, Inc. (NASDAQ:ARRS)’s shares inclined 0.54% to $32.32.
ARRIS Group, Inc. (ARRS) in a groundbreaking FCC proposal that launched a new standard for TV and paved the way for recently’s TV experiences.
ARRIS (ARRS) is celebrating this milestone at its office in San Diego, California—where the members of the design team pioneered the original system for digital TV. The esteemed members in attendance will comprise Dr. Jerry Heller, Dr. Woo Paik, Dr. Paul Moroney, Bob Rast, and Marc Tayer.
The San Diego team projected the first all-digital TV system to the FCC’s Advisory Committee on Advanced Television Service. This invention led to modern advances in TV—startning with digital satellite service in 1994, digital cable in 1996, and terrestrial over-the-air digital broadcasts, and ongoing with recently’s mobile and streaming Internet TV, DVR, 4K, and multiscreen experiences. Along the way, ARRIS has continued this pioneering legacy with innovations that have brought the future of TV to millions of consumers around the world.
ARRIS Group, Inc. provides media entertainment and data communications solutions in the United States and internationally. The company operates in two segments, Customer Premises Equipment and Network & Cloud. The Customer Premises Equipment segment offers various product solutions, counting set-top boxes, gateways, digital subscriber lines and cable modems, and embedded multimedia terminal adapters and voice/data modems that enable service providers to offer voice, video, and high-speed data services to residential and business subscribers.
ANADIGICS, Inc. (NASDAQ:ANAD)’s shares dropped -8.57% to $0.640.
ANADIGICS, Inc. (ANAD) introduced two new high-power GaN infrastructure line amplifiers for CATV systems at ANGA COM 2015. The ACA2455 and ACA4733 power doublers are optimized for fiber deep, Node+0 networks, and node segmentation/split upgrades by delivering world-class output power, linearity and efficiency. With only 12.7 Watts of DC power consumption, these new line amplifiers offer the lowest cost per bit for all-digital content delivery. This efficiency assists MSOs better manage operating costs over the life of the network.
ANADIGICS’ ACA2455 and ACA4733 line amplifiers combine the Company’s MESFET technology with a GaN output stage to deliver exceptional performance and reliability in CATV infrastructure applications. These highly linear power doublers provide 28 dB gain, +63 dBmV per channel output power, and +73.2 dBmV total composite power. The Company’s ACA2455 and ACA4733 GaN line amplifiers offer exceptional composite triple beat (CTB), composite second order (CSO), cross modulation, carrier-to-intermodulation noise (CIN), and modulation-error and bit-error ratio (MER and BER) characteristics for optimal performance in a fully-loaded spectrum.
ANADIGICS High-Power Line Amplifier Family Key Facts and Highlights:
- Highest single-device output power to support both analog/digital and completely digital CATV systems
- Industry’s highest performance to enable Node+0 system architectures without active components downstream of the fiber node
- GaN output stage enhances output power, ruggedness and efficiency
- GaAs driver stage provides exceptional linearity and reliability
ANADIGICS, Inc. designs, manufactures, and sells radio frequency (RF) semiconductor solutions for infrastructure and mobile communications, and data transmission markets. The companys product portfolio comprises line amplifiers, reverse path amplifiers, front-end integrated circuits (FEICs), and power amplifiers (PAs). Its CATV solutions comprise of line amplifiers, reverse path amplifiers, and other RF products that provide the critical link within CATV infrastructure communications networks, in addition to CPE devices, such as set-top boxes and cable modems.
At the end of Friday’s trade, Noranda Aluminum Holding Corporation (NYSE:NOR)‘s shares dipped -5.22% to $1.09.
Noranda Aluminum Holding Corporation (NOR) declared recently that its wholly-owned partner Noranda Bauxite Limited (“NBL”) has reached an interim agreement with the Government of Jamaica (the “GOJ”) regardinga dispute regarding production levies. The interim agreement addresses payments of production levies pending the conclusion of arbitration related to those levies, and will be in effect until the earlier of December 31, 2015 or the date on which an arbitration award is delivered.
Under the terms of the interim agreement, the GOJ has agreed to stay or discontinue its May 28, 2015 application for an interim injunction restraining NBL`s export of bauxite from Jamaica. NBL has agreed to provide interim levies to the GOJ in the form of cash and irrevocable letters of credit. NBL and the GOJ have agreed that amounts offered under the interim agreement will be without prejudice to any and all rights of either party to contend that no levy is payable or that another levy rate applies.
Noranda Aluminum Holding Corporation produces and sells primary aluminum and rolled aluminum coils in the United States. The company’s Bauxite segment mines, produces, and sells bauxite used for alumina production. Its Alumina segment refines and converts bauxite into alumina, which is used in the production of primary aluminum; and sells smelter grade alumina and alumina hydrate, or chemical-grade alumina. The company’s Primary Aluminum segment produces and sells aluminum products in various forms, such as billets, rods, sow and foundry, and commodity grade sow.
Thermo Fisher Scientific Inc. (NYSE:TMO), ended its Friday’s trading session with -0.38% loss, and closed at $130.02.
Thermo Fisher Scientific Inc. (TMO) declared that its board of directors has declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on July 15, 2015, to shareholders of record as of June 15, 2015.
Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables used in biological and medical research, discovery, and production of new drugs and vaccines, in addition to diagnosis of diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
